149 related articles for article (PubMed ID: 32891860)
1. From orexin receptor agonist YNT-185 to novel antagonists with drug-like properties for the treatment of insomnia.
Mezeiova E; Janockova J; Konecny J; Kobrlova T; Benkova M; Dolezal R; Prchal L; Karasova-Zdarova J; Soukup O; Korabecny J
Bioorg Chem; 2020 Oct; 103():104179. PubMed ID: 32891860
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptide orexin type-2 receptor agonist ameliorates narcolepsy-cataplexy symptoms in mouse models.
Irukayama-Tomobe Y; Ogawa Y; Tominaga H; Ishikawa Y; Hosokawa N; Ambai S; Kawabe Y; Uchida S; Nakajima R; Saitoh T; Kanda T; Vogt K; Sakurai T; Nagase H; Yanagisawa M
Proc Natl Acad Sci U S A; 2017 May; 114(22):5731-5736. PubMed ID: 28507129
[TBL] [Abstract][Full Text] [Related]
3. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?
Hoyer D; Jacobson LH
Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799
[TBL] [Abstract][Full Text] [Related]
4. [Development of a Therapeutic Drug for Narcolepsy].
Irukayama-Tomobe Y; Yanagisawa M
Brain Nerve; 2018 Nov; 70(11):1255-1263. PubMed ID: 30416119
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of novel orexin 2 receptor agonists based on naphthalene skeleton.
Hino T; Saitoh T; Nagumo Y; Yamamoto N; Kutsumura N; Irukayama-Tomobe Y; Ishikawa Y; Tanimura R; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2022 Mar; 59():128530. PubMed ID: 35007725
[TBL] [Abstract][Full Text] [Related]
6. Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant.
Yin J; Mobarec JC; Kolb P; Rosenbaum DM
Nature; 2015 Mar; 519(7542):247-50. PubMed ID: 25533960
[TBL] [Abstract][Full Text] [Related]
7. Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia.
Bonaventure P; Shelton J; Yun S; Nepomuceno D; Sutton S; Aluisio L; Fraser I; Lord B; Shoblock J; Welty N; Chaplan SR; Aguilar Z; Halter R; Ndifor A; Koudriakova T; Rizzolio M; Letavic M; Carruthers NI; Lovenberg T; Dugovic C
J Pharmacol Exp Ther; 2015 Sep; 354(3):471-82. PubMed ID: 26177655
[TBL] [Abstract][Full Text] [Related]
8. Nonpeptide Orexin-2 Receptor Agonist Attenuates Morphine-induced Sedative Effects in Rats.
Toyama S; Shimoyama N; Tagaito Y; Nagase H; Saitoh T; Yanagisawa M; Shimoyama M
Anesthesiology; 2018 May; 128(5):992-1003. PubMed ID: 29521652
[TBL] [Abstract][Full Text] [Related]
9. Identification of MK-8133: An orexin-2 selective receptor antagonist with favorable development properties.
Kuduk SD; Skudlarek JW; DiMarco CN; Bruno JG; Pausch MH; O'Brien JA; Cabalu TD; Stevens J; Brunner J; Tannenbaum PL; Garson SL; Savitz AT; Harrell CM; Gotter AL; Winrow CJ; Renger JJ; Coleman PJ
Bioorg Med Chem Lett; 2015 Jun; 25(12):2488-92. PubMed ID: 25981685
[TBL] [Abstract][Full Text] [Related]
10. Investigation of New Orexin 2 Receptor Modulators Using
Janockova J; Dolezal R; Nepovimova E; Kobrlova T; Benkova M; Kuca K; Konecny J; Mezeiova E; Melikova M; Hepnarova V; Ring A; Soukup O; Korabecny J
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423961
[TBL] [Abstract][Full Text] [Related]
11. Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.
Betschart C; Hintermann S; Behnke D; Cotesta S; Fendt M; Gee CE; Jacobson LH; Laue G; Ofner S; Chaudhari V; Badiger S; Pandit C; Wagner J; Hoyer D
J Med Chem; 2013 Oct; 56(19):7590-607. PubMed ID: 23964859
[TBL] [Abstract][Full Text] [Related]
12. Involvement of orexin type-2 receptors in genetic absence epilepsy rats.
Toplu A; Mutlu N; Erdeve ET; Sariyildiz Ö; Çelik M; Öz-Arslan D; Akman Ö; Molnár Z; Çarçak N; Onat F
Front Neurol; 2023; 14():1282494. PubMed ID: 38107640
[TBL] [Abstract][Full Text] [Related]
13. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
Yukitake H; Fujimoto T; Ishikawa T; Suzuki A; Shimizu Y; Rikimaru K; Ito M; Suzuki M; Kimura H
Pharmacol Biochem Behav; 2019 Dec; 187():172794. PubMed ID: 31654653
[TBL] [Abstract][Full Text] [Related]
14. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists.
Nagahara T; Saitoh T; Kutsumura N; Irukayama-Tomobe Y; Ogawa Y; Kuroda D; Gouda H; Kumagai H; Fujii H; Yanagisawa M; Nagase H
J Med Chem; 2015 Oct; 58(20):7931-7. PubMed ID: 26267383
[TBL] [Abstract][Full Text] [Related]
15. Suvorexant: a novel therapy for the treatment of insomnia.
Howland RH
J Psychosoc Nurs Ment Health Serv; 2014 Oct; 52(10):23-6. PubMed ID: 25291725
[TBL] [Abstract][Full Text] [Related]
16. Orexin receptor antagonists: medicinal chemistry and therapeutic potential.
Roecker AJ; Coleman PJ
Curr Top Med Chem; 2008; 8(11):977-87. PubMed ID: 18673167
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists.
Zhang D; Perrey DA; Decker AM; Langston TL; Mavanji V; Harris DL; Kotz CM; Zhang Y
J Med Chem; 2021 Jun; 64(12):8806-8825. PubMed ID: 34101446
[TBL] [Abstract][Full Text] [Related]
18. Essential structure of orexin 1 receptor antagonist YNT-707, Part IV: The role of D-ring in 4,5-epoxymorphinan on the orexin 1 receptor antagonistic activity.
Saitoh T; Seki K; Nakajima R; Yamamoto N; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Tanimura R; Yanagisawa M; Nagase H
Bioorg Med Chem Lett; 2019 Sep; 29(18):2655-2658. PubMed ID: 31375290
[TBL] [Abstract][Full Text] [Related]
19. The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia.
Coleman PJ; Gotter AL; Herring WJ; Winrow CJ; Renger JJ
Annu Rev Pharmacol Toxicol; 2017 Jan; 57():509-533. PubMed ID: 27860547
[TBL] [Abstract][Full Text] [Related]
20. [Preclinical and clinical efficacy of orexin receptor antagonist Lemborexant (Dayvigo
Koebisu M; Koyama N; Nishida M; Muramoto K
Nihon Yakurigaku Zasshi; 2021; 156(2):114-119. PubMed ID: 33642529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]